发布求助
文献互助 智能选刊 最新文献

Pharmadeals Review最新文献

筛选
英文 中文
Shire Progresses Rare Disease Strategy with US$4.2 B ViroPharma Purchase Shire以42亿美元收购ViroPharma推进罕见病战略
Pharmadeals Review Pub Date : 2013-11-26 DOI: 10.3833/PDR.V2013I11.1993
Heather Cartwright
{"title":"Shire Progresses Rare Disease Strategy with US$4.2 B ViroPharma Purchase","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I11.1993","DOIUrl":"https://doi.org/10.3833/PDR.V2013I11.1993","url":null,"abstract":"In order to attain a dominant position in the hereditary angioedema (HAE) market and to increase the size of its rare disease business unit, Shire has agreed to acquire ViroPharma for approximately US$4.2 B in cash. With the acquisition, Shire will gain Cinryze® (C1 esterase inhibitor [human]), a prophylactic HAE treatment that will complement its existing portfolio product Firazyr® (icatibant), which is indicated for acute HAE attacks. The acquisition also offers Shire the potential for annual cost synergies of approximately US$150 M by 2015 and sizeable tax savings.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89635197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salix Adds to Gastroenterology Franchise with US$2.6 B Santarus Acquisition Salix以26亿美元收购Santarus，增加胃肠病学特许经营权
Pharmadeals Review Pub Date : 2013-11-22 DOI: 10.3833/PDR.V2013I11.1992
Heather Cartwright
{"title":"Salix Adds to Gastroenterology Franchise with US$2.6 B Santarus Acquisition","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I11.1992","DOIUrl":"https://doi.org/10.3833/PDR.V2013I11.1992","url":null,"abstract":"Gastroenterology specialist Salix Pharmaceuticals has agreed to acquire Santarus in an all-cash transaction that values the company at approximately US$2.6 B. The acquisition will strengthen Salix’s commercial presence in gastroenterology, providing it with access to the primary care market and an ulcerative colitis drug with high growth potential. It will also provide diversification into new therapy areas, adding products such as Glumetza® (metformin extended-release) for type 2 diabetes and Fenoglide® (fenofibrate) for high cholesterol. The combined company will have estimated 2013 pro forma revenue of US$1.3 B from a portfolio of 22 marketed products.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"17 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91496694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roche Signals Return to Antibiotics Development with Polyphor Licensing Deal 罗氏与多肽授权交易标志着抗生素开发的回归
Pharmadeals Review Pub Date : 2013-11-18 DOI: 10.3833/PDR.V2013I11.1990
Heather Cartwright
{"title":"Roche Signals Return to Antibiotics Development with Polyphor Licensing Deal","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I11.1990","DOIUrl":"https://doi.org/10.3833/PDR.V2013I11.1990","url":null,"abstract":"After exiting antibiotics R&D in 2000 with the spin out of its anti-infectives discovery division into Basilea Pharmaceutica, Roche has highlighted its renewed commitment to the field by licensing global rights to develop and commercialise Polyphor’s macrocyclic antibiotic POL7080, which has potential in the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Derived from Polyphor’s protein epitope mimetics (PEM) drug discovery platform, POL7080 has demonstrated clinical safety and tolerability in a Phase I study. The deal follows a February 2013 collaboration between Genentech and RQx Pharmaceuticals for the discovery and development of novel small molecule antibiotics active against an undisclosed target.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89226318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pfizer Mitigates Tanezumab Risk with Potential US$1.8 B Deal with Eli Lilly 辉瑞与礼来达成18亿美元交易降低Tanezumab风险
Pharmadeals Review Pub Date : 2013-11-13 DOI: 10.3833/PDR.V2013I11.1989
Heather Cartwright
{"title":"Pfizer Mitigates Tanezumab Risk with Potential US$1.8 B Deal with Eli Lilly","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I11.1989","DOIUrl":"https://doi.org/10.3833/PDR.V2013I11.1989","url":null,"abstract":"Three years after development of the entire class of nerve growth factor (NGF) inhibitors was put on clinical hold by the US FDA over serious safety concerns related to joint destruction, Pfizer has decided to continue Phase III development of its anti-NGF antibody tanezumab in collaboration with Eli Lilly as part of a deal potentially worth up to US$1.8 B. In March 2012, an FDA advisory committee agreed that NGF inhibitors could be studied in certain patient populations. Pfizer hopes to resume studies of the drug in osteoarthritis, chronic low back pain and cancer pain after submitting nonclinical data to the FDA in the first half of 2014.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82624811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lundbeck and Otsuka Expand Alliance with Deal for Late-Stage Alzheimer’s Disease Programme 灵北和大冢扩大合作，达成晚期阿尔茨海默病项目协议
Pharmadeals Review Pub Date : 2013-11-04 DOI: 10.3833/pdr.v2013i4.1921
Heather Cartwright
{"title":"Lundbeck and Otsuka Expand Alliance with Deal for Late-Stage Alzheimer’s Disease Programme","authors":"Heather Cartwright","doi":"10.3833/pdr.v2013i4.1921","DOIUrl":"https://doi.org/10.3833/pdr.v2013i4.1921","url":null,"abstract":"In the largest single product licensing deal of 2013 so far, H. Lundbeck and Otsuka Pharmaceutical have partnered for the development of Lu AE58054, a selective 5HT6 receptor antagonist that has completed a Phase II trial in patients with moderate Alzheimer’s disease. Otsuka will gain co-development and co-commercialisation rights to Lu AE58054 in the US, Canada, major European countries, Nordic countries and East Asia, including Japan. The deal represents an expansion of the companies’ November 2011 alliance for the co-development and co-commercialisation of up to five CNS products.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76321615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hutchison MediPharma Partners with Eli Lilly to Advance Development of Fruquintinib in China 和记黄埔医药与礼来合作推进fruquininib在中国的开发
Pharmadeals Review Pub Date : 2013-10-23 DOI: 10.3833/PDR.V2013I10.1985
Heather Cartwright
{"title":"Hutchison MediPharma Partners with Eli Lilly to Advance Development of Fruquintinib in China","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I10.1985","DOIUrl":"https://doi.org/10.3833/PDR.V2013I10.1985","url":null,"abstract":"Hutchison MediPharma (HMP), the R&D division of the Chinese pharmaceutical and healthcare group Hutchison Chi-Med, has partnered with Eli Lilly for second time with a licensing, co-development and commercialisation agreement for its Phase II cancer drug fruquintinib (HMPL-013), a highly selective small molecule inhibitor of the vascular endothelial growth factor (VEGF) receptor tyrosine kinases with potential in the treatment of advanced refractory solid tumours. The two companies will share development costs in China, thus allowing HMP to expand the clinical programme for the drug to multiple tumour types.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"16 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77702927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Celgene Pays US$100 M for Option to Buy Acetylon and Partners with Array BioPharma Celgene支付1亿美元购买Acetylon的选择权，并与Array BioPharma合作
Pharmadeals Review Pub Date : 2013-10-08 DOI: 10.3833/PDR.V2013I8.1971
Heather Cartwright
{"title":"Celgene Pays US$100 M for Option to Buy Acetylon and Partners with Array BioPharma","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I8.1971","DOIUrl":"https://doi.org/10.3833/PDR.V2013I8.1971","url":null,"abstract":"Celgene has agreed to pay Acetylon Pharmaceuticals US$100 M upfront in order to obtain an exclusive option to buy the company at a future date for at least US$500 M and potentially more than US$1.6 B. Acetylon will use the non-dilutive funding to advance its portfolio of selective HDAC (histone deacetylase) inhibitors, including its Phase I/II candidate ACY-1215 (rocilinostat) for multiple myeloma. Celgene has also formed a global R&D collaboration with Array BioPharma focused on a preclinical development programme targeting a novel inflammation pathway.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90138717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Forma Therapeutics Partners with Celgene in its Largest Deal to Date Forma Therapeutics与Celgene达成迄今为止最大的交易
Pharmadeals Review Pub Date : 2013-09-05 DOI: 10.3833/PDR.V2013I5.1936
Heather Cartwright
{"title":"Forma Therapeutics Partners with Celgene in its Largest Deal to Date","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I5.1936","DOIUrl":"https://doi.org/10.3833/PDR.V2013I5.1936","url":null,"abstract":"Celgene has become Forma Therapeutics’ latest partner with a deal to discover, develop and commercialise drug candidates that regulate targets involved in protein homeostasis. Celgene will have the option to obtain the ex-US rights to multiple drug candidates after evaluating selected targets and lead assets in protein homeostasis pathways during the preclinical phase of the collaboration. In an evolution of deal structure for the company, Forma will be responsible for advancing compounds through the completion of Phase I in collaboration with its partner TGen Drug Development.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80293004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Jazz and Concert Collaborate to Develop Deuterium-Modified Version of Xyrem® Jazz和Concert合作开发氘修饰版Xyrem®
Pharmadeals Review Pub Date : 2013-09-03 DOI: 10.3833/PDR.V2013I3.1908
Heather Cartwright
{"title":"Jazz and Concert Collaborate to Develop Deuterium-Modified Version of Xyrem®","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I3.1908","DOIUrl":"https://doi.org/10.3833/PDR.V2013I3.1908","url":null,"abstract":"Jazz Pharmaceuticals has licensed exclusive worldwide rights to develop and commercialise Concert Pharmaceuticals’ deuterium-modified analogues of sodium oxybate (D-SXB), including its lead compound C-10323. In doing so, the company is looking to develop a follow-on version of its key commercial asset Xyrem® (sodium oxybate), which is indicated for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy patients. Preclinical data suggest that selective deuterium incorporation can stabilise sodium oxybate in vivo, which could provide for an improved dosing schedule. An IND application for C-10323 is planned for later in 2013.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90199593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ligand Licenses Injectable Formulation of Topiramate to Start-Up CURx 配体许可托吡酯注射制剂启动曲线
Pharmadeals Review Pub Date : 2013-08-21 DOI: 10.3833/PDR.V2013I8.1973
Heather Cartwright
{"title":"Ligand Licenses Injectable Formulation of Topiramate to Start-Up CURx","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I8.1973","DOIUrl":"https://doi.org/10.3833/PDR.V2013I8.1973","url":null,"abstract":"Ligand Pharmaceuticals has licensed global rights to its Captisol-enabled® topiramate injection to start-up CURx Pharmaceuticals for the treatment of partial onset or primary generalised tonic-clonic seizures in hospitalised epilepsy patients who are unable to take oral topiramate. Captisol® is drug formulation system that is designed to optimise the solubility and stability of drugs and which Ligand gained with its 2011 acquisition of CyDex Pharmaceuticals. In a Phase I clinical trial, the drug candidate demonstrated a faster onset of action than oral topiramate.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"117 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79076119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信